Baillie Gifford & Co
ICPT

Baillie Gifford & Co’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Baillie Gifford & Co’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-101
Closed -$1.36K – 455
2023
Q1 		$1.36K Hold
101
– – ﹤0.01% 439
2022
Q4 		$1.25K Hold
101
– – ﹤0.01% 478
2022
Q3 		$1K Hold
101
– – ﹤0.01% 483
2022
Q2 		$1K Hold
101
– – ﹤0.01% 487
2022
Q1 		$2K Hold
101
– – ﹤0.01% 491
2021
Q4 		$2K Hold
101
– – ﹤0.01% 496
2021
Q3 		$1K Hold
101
– – ﹤0.01% 491
2021
Q2 		$2K Hold
101
– – ﹤0.01% 470
2021
Q1 		$2K Buy
101
+15
+17% +$418 ﹤0.01% 444
2020
Q4 		$2K Buy
+86
New +$2.85K ﹤0.01% 427

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Baillie Gifford & Co's ICPT Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 101 shares — an estimated $1.36K sold.

Baillie Gifford & Co first reported a position in ICPT in Q4 2020 and held it in 10 quarters. The position peaked at $2K in Q1 2022. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 101 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.36K.
  • Baillie Gifford & Co first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Intercept Pharmaceuticals, Inc. position peaked at $2K in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.